|
gptkbp:instanceOf
|
gptkb:biomarker
|
|
gptkbp:abbreviation
|
gptkb:TMB
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
immunotherapy response
|
|
gptkbp:canVaryBy
|
gptkb:tumor_subtype
cancer type
|
|
gptkbp:FDAApprovalFor
|
pembrolizumab in solid tumors
|
|
gptkbp:higherTMBAssociatedWith
|
better response to immune checkpoint inhibitors
|
|
gptkbp:measures
|
next-generation sequencing
whole exome sequencing
mutations per megabase
|
|
gptkbp:regulates
|
tumor immunogenicity
|
|
gptkbp:relatedTo
|
microsatellite instability
neoantigen load
|
|
gptkbp:standardizedBy
|
FoundationOne CDx assay
MSK-IMPACT assay
|
|
gptkbp:studiedIn
|
gptkb:neuroblastoma
gptkb:Wilms_tumor
gptkb:carcinoid_tumor
gptkb:leukemia
gptkb:cancer
gptkb:medulloblastoma
gptkb:germ_cell_tumor
gptkb:renal_cell_carcinoma
gptkb:bladder_cancer
gptkb:endometrial_cancer
gptkb:rhabdomyosarcoma
gptkb:retinoblastoma
gptkb:pheochromocytoma
gptkb:Ewing_sarcoma
gptkb:paraganglioma
gptkb:glioma
gptkb:testicular_cancer
gptkb:chordoma
gptkb:melanoma
colorectal cancer
esophageal cancer
liver cancer
mesothelioma
multiple myeloma
pancreatic cancer
prostate cancer
adrenocortical carcinoma
head and neck cancer
osteosarcoma
gastric cancer
malignant peripheral nerve sheath tumor
|
|
gptkbp:thresholdForHighTMB
|
10 mutations per megabase
|
|
gptkbp:usedAs
|
prognostic biomarker
predictive biomarker
|
|
gptkbp:usedIn
|
cancer research
oncology
|
|
gptkbp:bfsParent
|
gptkb:TMB
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tumor Mutational Burden
|